Randomization and study interventions
After written informed consent was obtained from each patient, patients were randomly assigned in a 1:1 ratio to receive either standard of care with unfractionated heparin or low molecular weight heparin at a prophylactic dose or therapeutic anticoagulation with rivaroxaban during hospitalization followed by a four-week period of thromboprophylaxis with rivaroxaban. The randomization was done using a central, web-based system and was stratified by: site, gender, age (< 65 versus ≥ 65 years), kidney function (eGFR ≥ 30 mL/min/1.73 mThe patients that were assigned to the standard of care group received unfractionated heparin or a low molecular weight heparin at a prophylactic dose for at least 7 days or until discharge (if hospitalized), whichever occurred later. The patients on the intervention arm received rivaroxaban 20 mg once daily (adjusted to 15 mg once daily for patients with an eGFR < 50 mL/min/1.73 mStudy flow and efficacy outcomesThe assessment at baseline included demographic characteristics, risk factors, medical history, and laboratory data. Follow-up was done at day 7 and 35 post randomization to assess study outcomes. Additional safety information was collected by telephone at day 60 post randomization.